Biotechnological agents for patients with tumor necrosis factor receptor associated periodic syndrome: therapeutic outcome and predictors of response: real-life data from the AIDA Network

Key Findings

• ●Anakinra effective in ~90% of TRAPS patients
• ●Complete remission in ~67% with anakinra
• ●15% partial response, 9% lack of efficacy with anakinra

Referenced in (1 disease)

No validation events recorded yet. Source will be checked on the next kipine-source-validator run.